DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “hold” rating reaffirmed by equities research analysts at Robert W. Baird in a research report issued on Sunday. They presently have a $79.00 target price on the medical device company’s stock. Robert W. Baird’s target price points to a potential upside of 10.86% from the company’s previous close.

A number of other brokerages have also weighed in on DXCM. BidaskClub lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. BMO Capital Markets reiterated a “buy” rating and set a $105.00 target price on shares of DexCom in a research report on Thursday, July 13th. Piper Jaffray Companies reiterated an “overweight” rating and set a $78.00 target price (down previously from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. Finally, Oppenheimer Holdings, Inc. set a $92.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $87.64.

DexCom (DXCM) traded up 0.04% during mid-day trading on Friday, reaching $71.26. 1,231,920 shares of the company’s stock were exchanged. The company has a 50-day moving average of $71.90 and a 200-day moving average of $74.32. DexCom has a 52-week low of $57.68 and a 52-week high of $94.79. The stock’s market cap is $6.17 billion.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.24) earnings per share. Equities research analysts anticipate that DexCom will post ($0.77) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/dexcom-inc-dxcm-receives-hold-rating-from-robert-w-baird.html.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $69.07, for a total transaction of $414,420.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $69.06, for a total transaction of $220,992.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,179 shares of company stock valued at $2,282,217. 1.70% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of DXCM. Janus Henderson Group PLC raised its stake in shares of DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after acquiring an additional 6,822,023 shares in the last quarter. BlackRock Inc. raised its stake in shares of DexCom by 5,000.4% during the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after acquiring an additional 4,079,283 shares in the last quarter. Winslow Capital Management LLC purchased a new position in shares of DexCom during the second quarter worth approximately $117,451,000. FMR LLC raised its stake in shares of DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after acquiring an additional 978,898 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of DexCom by 27.3% during the second quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock worth $237,221,000 after acquiring an additional 696,199 shares in the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.